Background: @entity41 ( @entity41 ) assessment provides a powerful prognostic factor for therapeutic stratification in @entity981 ( @entity981 ). @entity450 ( @entity450 ) has the potential for a rapid and sensitive identification of high risk @entity1 . Our group has previously published that @entity41 levels analyzed by clone specific Ig/TcR-QPCR and @entity450 were concordant at a sensitivity of 10(-4) . Here we report the @entity450 methodological aspects from this multi-center experience. Methods: @entity41 was assessed by @entity450 in 1030 follow-up samples from 265 pediatric and adult @entity1 with de novo @entity981 treated in the FRALLE, EORTC or GRALL clinical trials. @entity41 assessment as applied by the eight participating @entity450 laboratories is described in detail regarding cell preparation, @entity1778 -associated immunophenotype (LAIP) markers and data analysis. Samples were obtained from bone marrow (BM) and peripheral blood (PB). Immunostaining was performed after erythrocyte lysis or Ficoll enrichment. Results: This study confirms the applicability of @entity450 -based @entity41 assessment in 97% of @entity1 with @entity981 at the 10(-4) cut-off. @entity41 values after Ficoll enrichment and erythrocyte lysis were found comparable. Higher @entity41 values were obtained in BM than in PB, especially for B-lineage @entity981 . Conclusions: Measurement of @entity41 by @entity450 at the 10(-4) cut-off is applicable within a few hours for almost all @entity1 and using a comparable analytical strategy allows for multicenter collaborative studies. The method can be introduced in a strategy aimed at defining the risk of failure of @entity1 with childhood or adult @entity981 .    2014 Clinical Cytometry Society.

Methodological aspects of minimal residual disease assessment by flow cytometry in XXXX : A French multicenter study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity981 :: ('MESH:D054198', 'Disease') :: ['ALL', 'acute lymphoblastic leukemia'] @entity41 :: ('MESH:D018365', 'Disease') :: ['MRD', 'Minimal residual disease'] @entity450 :: ('MESH:D006940', 'Disease') :: ['MFC', 'Multiparameter flow cytometry'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemia']
@entity981 :: (MESH:D054198,Disease) :: ['acute lymphoblastic leukemia']
